Masahiro Shiokawa

Masahiro Shiokawa


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MSMasahiro Shiokawa
Masahiro Shiokawa
YKYuzo Kodama
Yuzo Kodama
KSKiyotoshi Sekiguchi
Kiyotoshi Sekiguchi
TKTakeshi Kuwada
Takeshi Kuwada
TTTeruko Tomono
Teruko Tomono
TCTsutomu Chiba
Tsutomu Chiba
The extracellular matrix protein laminin 511 is an autoantigen involved in the pathophysiology of autoimmune pancreatitis.

1 June 2021 in Gastroenterology
Verified
Journal Article
Open access
PDF file
TKTakeshi Kuwada
Takeshi Kuwada
MSMasahiro Shiokawa
Masahiro Shiokawa
YKYuzo Kodama
Yuzo Kodama
SOSakiko Ota
Sakiko Ota
NKNobuyuki Kakiuchi
Nobuyuki Kakiuchi
HSHiroshi Seno
Hiroshi Seno
Background and Aims Ulcerative colitis is the most frequent type of inflammatory bowel disease and is characterized by colonic epithelial cell damage. Although involvement of autoimmunity has been suggested in ulcerative colitis, specific autoantigens/antibodies have yet to be elucidated. Methods Using 23 recombinant integrin proteins, we performed enzyme-linked immunosorbent assays on sera from patients with ulcerative colitis and controls. Integrin expression and IgG binding in the colon tissues of patients with ulcerative colitis and controls were examined using immunofluorescence and coimmunoprecipitation, respectively. The blocking activity of autoantibodies was examined using solid-phase binding and cell adhesion assays. Results Screening revealed that patients with ulcerative colitis had IgG antibodies against integrin αvβ6. In the training and validation groups, 103 of 112 (92.0%) patients with ulcerative colitis and only 8 of 155 (5.2%) controls had anti–integrin αvβ6 antibodies (P < .001), resulting in a sensitivity of 92.0% and a specificity of 94.8% for diagnosing ulcerative colitis. Anti–integrin αvβ6 antibody titers coincided with ulcerative colitis disease activity, and IgG1 was the major subclass. Patient IgG bound to the integrin αvβ6 expressed on colonic epithelial cells. Moreover, IgG of patients with ulcerative colitis blocked integrin αvβ6–fibronectin binding through an RGD (Arg-Gly-Asp) tripeptide motif and inhibited cell adhesion. Conclusions A significant majority of patients with ulcerative colitis had autoantibodies against integrin αvβ6, which may serve as a potential diagnostic biomarker with high sensitivity and specificity.

13 June 2022 in Gastroenterology
Verified
Journal Article
Open access
PDF file
YMYuya Muramoto
Yuya Muramoto
HNHiroshi Nihira
Hiroshi Nihira
MSMasahiro Shiokawa
Masahiro Shiokawa
KIKazushi Izawa
Kazushi Izawa
EHEitaro Hiejima
Eitaro Hiejima
TYTakahiro Yasumi
Takahiro Yasumi
Japan Pediatric Inflammatory Bowel Disease Working Group: Takeshi Kuwada (Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan), Katsuhiro Arai (Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan), Takahiro Kudo (Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan), Itaru Iwama (Division of Gastroenterology and Hepatology, Saitama Children’s Medical Center, Saitama, Japan), Tatsuki Mizuochi (Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan), Tsuyoshi Sogo (Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohama-shi Tobu Hospital, Yokohama, Japan), Emiri Kaji (Department of Pediatrics, Osaka Medical College, Osaka, Japan), Takehiko Doi (Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan), Toshinao Kawai (Division of Immunology, National Center for Child Health and Development, Tokyo, Japan), Masami Inoue (Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Osaka, Japan), Yoji Sasahara (Department of Pediatrics, Tohoku University, Sendai, Japan), Hidenori Ohnishi (Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan), Satoshi Okada (Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University), Hirokazu Kanegane (Department of Child Health and Development, Tokyo Medical and Dental University, Tokyo, Japan), Ryuta Nishikomori (Department of Pediatrics and Child Health, Kurume University School of Medicine), Hirotaka Shimizu (Division of Gastroenterology, National Center for Child Health and Development), Ichiro Takeuchi (Division of Gastroenterology, National Center for Child Health and Development), Natsuki Ito (Department of Pediatrics, Juntendo University Faculty of Medicine), Ryosuke Yasuda (Department of Pediatrics and Child Health, Kurume University School of Medicine), Ayano Inui (Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohama-shi Tobu Hospital), Yuri Etani (Department of Gastroenterology, Nutrition and Endocrinology, Osaka Women’s and Children’s Hospital, Osaka, Japan), Hajime Yamazaki (Department of Community Medicine, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto, Japan), Yoshihiro Nishikawa (Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine), Yoshitaka Honda (Department of Pediatrics, Kyoto University, and Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan), Norimitsu Uza (Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine), Junko Takita (Department of Pediatrics, Kyoto University), Tsutomu Chiba (Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, and Kansai Electric Power Hospital, Osaka, Japan), and Takahiro Yasumi (Department of Pediatrics, Kyoto University).

13 June 2023 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
HYHiroyuki Yoshida
Hiroyuki Yoshida
MSMasahiro Shiokawa
Masahiro Shiokawa
TKTakeshi Kuwada
Takeshi Kuwada
YMYuya Muramoto
Yuya Muramoto
SOSakiko Ota
Sakiko Ota
HSHiroshi Seno
Hiroshi Seno
Background: Patients with primary sclerosing cholangitis (PSC) possess autoantibodies against biliary epithelial cells. However, the target molecules remain unknown. Methods: The sera of patients with PSC and controls were subjected to enzyme-linked immunosorbent assays to detect autoantibodies using recombinant integrin proteins. Integrin αvβ6 expression in the bile duct tissues was examined using immunofluorescence. The blocking activity of the autoantibodies was examined using solid-phase binding assays. Results: Anti-integrin αvβ6 antibodies were detected in 49/55 (89.1%) patients with PSC and 5/150 (3.3%) controls (P < 0.001), with a sensitivity and specificity of 89.1% and 96.7%, respectively, for PSC diagnosis. When focusing on the presence or absence of IBD, the proportion of the positive antibodies in PSC with IBD was 97.2% (35/36) and that in PSC alone was 73.7% (14/19) (P = 0.008). Integrin αvβ6 was expressed in bile duct epithelial cells. Immunoglobulin (Ig)G from 15/33 patients with PSC blocked integrin αvβ6-fibronectin binding through an RGD (Arg–Gly–Asp) tripeptide motif. Conclusions: Autoantibodies against integrin αvβ6 were detected in most patients with PSC; anti-integrin αvβ6 antibody may serve as a potential diagnostic biomarker for PSC.

9 March 2024 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MYMasataka Yokode
Masataka Yokode
MSMasahiro Shiokawa
Masahiro Shiokawa
HKHisato Kawakami
Hisato Kawakami
TKTakeshi Kuwada
Takeshi Kuwada
YNYoshihiro Nishikawa
Yoshihiro Nishikawa
HSHiroshi Seno
Hiroshi Seno
Background: No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis. Methods: Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients. Results: Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC. Conclusions: Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis.

28 November 2024 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
MOMakoto Okabe
Makoto Okabe
SYShuji Yamamoto
Shuji Yamamoto
MSMasahiro Shiokawa
Masahiro Shiokawa
THTadakazu Hisamatsu
Tadakazu Hisamatsu
HYHajime Yamazaki
Hajime Yamazaki
HSHiroshi Seno
Hiroshi Seno
Background: A serum biomarker for diagnosing ulcerative colitis (UC) remains to be established. Although we recently reported an anti-integrin αvβ6 antibody (V6 Ab) for diagnosing UC with high sensitivity and specificity, no large-scale validation study exists. This study aimed to validate the diagnostic value of V6 Ab for UC using a nationwide multicenter cohort study. Methods: We measured V6 Ab titers in patients definitively diagnosed with UC, Crohn’s disease (CD), or other gastrointestinal disorders (OGDs). The primary outcome was the diagnostic value of V6 Ab. Secondary outcomes were factors associated with false-negative results in patients with UC and false-positive results in patients without UC and the heterogeneity of the diagnostic value of V6 Ab among the participating facilities. Results: We enrolled 1241, 796, and 206 patients with UC, CD, and OGD, respectively, from 28 Japanese high-volume referral centers. The diagnostic sensitivity of V6 Ab for UC was 87.7%, and its specificities for CD and OGDs were 82.0% and 87.4%, respectively. Multivariable logistic regression analysis showed that false-negative results were associated with older age at the time of sample collection, current smokers, lower partial Mayo score, and not receiving advanced therapies in patients with UC, and false-positive results were associated with colonic CD in patients with CD. No factor was associated with false-positive results in patients with OGDs. There were no significant differences in the diagnostic value of V6 Ab among the centers. Conclusions: The diagnostic value of V6 Ab for UC was validated in the large-scale nationwide multicenter study.